OBJ appoints Paul Peros as CEO of new device business, page-44

I find those complaining and flagging the doom and gloom of a CR quite entertaining. The new board have clearly gone about establishing significant growth platforms behind the scenes without any fanfare.

There are more to come shortly I have no doubt. I also wouldn’t expect a salary of the nature of Paul Peros’ would be paid without already having established the platforms for serious deals in the pipeline.

In doing so no lofty ‘fanciful collaborations’ have been leaked to shareholders like Pfizer, GSK, the list did go on with the previous board. They are announcing facts.

Money makes money. Yes, further dilution is far from ideal but this is the new board’s first crack at it and they will need money to have a crack at it. To me, they have built the platforms discretely and methodically and deserve a shot.

So for those complaining about a CR, please enlighten us on how you would approach it? I mean this sincerely as I would be fascinated with your suggestions.